GlassScriptPhysician profile
Michael Van Pelt
NPI 1780238436
$1,560.07
in general payments reported to CMS, 2019-2025
25 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $324 · 2023: $905 · 2024: $47.26 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $195.41 | 2025 | Arrow |
| Musculoskeletal Transplant Foundation INC. | $179.84 | 2023 | |
| Abbvie INC. | $173.76 | 2022-2023 | |
| Novo Nordisk INC | $158.38 | 2022-2023 | Wegovy |
| Amgen INC. | $113.61 | 2022-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $88.74 | 2023-2024 | Veozah, Myrbetriq |
| Globus Medical, INC. | $88.38 | 2025 | Senza |
| Pfizer INC. | $76.41 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $71.54 | 2022-2023 | |
| Corium, LLC | $70.72 | 2022-2023 | Azstarys |
| Gilead Sciences, INC. | $45.81 | 2023 | |
| Glaxosmithkline, LLC. | $43.96 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $29.13 | 2022 | |
| Lilly USA, LLC | $27.53 | 2022-2023 | Mounjaro |
| Hologic Sales and Service, LLC | $23.49 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.23 | 2023 | |
| Exact Sciences Corporation | $21.90 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $19.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.23 | 2023 | Quviviq |
| Exeltis, USA INC. | $18.01 | 2023 | Slynd |
| Janssen Pharmaceuticals, INC | $16.50 | 2023 | Spravato |
| Lucid Diagnostics INC. | $15.79 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.40 | 2022 | |
| Viiv Healthcare Company | $12.88 | 2022 | |
| Merck Sharp & Dohme LLC | $12.80 | 2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Van Pelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.